🇺🇸 FDA
Company

SUPERNUS

SUPERNUS PHARMACEUTICALS, INC.

SUPN pharma USA

Quick answer

SUPERNUS is a pharma company (SUPN) headquartered in ROCKVILLE, MD, USA with 24 tracked pipeline programs.

Pipeline (24)

project

Brexanolone

Post Partum Depression

Phase 3 · small_molecule · completed

1 trials project

MYOBLOC

Sialorrhea

Phase 3 · small_molecule · completed

2 trials project

MYOBLOC Low Dose

Sialorrhea

Phase 3 · small_molecule · terminated

1 trials project

Oxcarbazepine XR

Partial Epilepsy

Phase 3 · small_molecule · completed

1 trials project

Phase 2; Low Dose MYOBLOC

Spasticity

Phase 3 · small_molecule · active

1 trials project

Phase 2; Low Dose MYOBLOC (15,000 Units)

Spasticity

Phase 3 · small_molecule · terminated

1 trials project

Placebo

Postpartum Depression

Phase 3 · small_molecule · completed

2 trials project

Placebo

Attention-Deficit/Hyperactivity Disorder (ADHD)

Phase 3 · small_molecule · completed

2 trials project

Placebo

ADHD

Phase 3 · small_molecule · completed

5 trials project

Placebo

Epilepsies, Partial

Phase 3 · small_molecule · completed

1 trials project

SAGE-547

Super-refractory Status Epilepticus

Phase 3 · small_molecule · completed

2 trials project

SAGE-718

Huntington's Disease

Phase 3 · small_molecule · terminated

2 trials project

SPN-810

Attention Deficit Hyperactivity Disorder (ADHD)

Phase 3 · small_molecule · terminated

2 trials project

SPN-810

Attention Deficit Hyperactivity Disorder

Phase 3 · small_molecule · terminated

1 trials project

SPN-810 (18 mg)

Attention Deficit Hyperactivity Disorder (ADHD)

Phase 3 · small_molecule · completed

2 trials project

apomorphine infusion

Idiopathic Parkinson's Disease

Phase 3 · small_molecule · active

1 trials project

BIS-001ER

Focal Impaired Awareness Seizures

Phase 2 · small_molecule · active

1 trials project

Botulinum Toxin Type B (Myobloc)

Drooling

Phase 2 · mab · completed

1 trials project

Brexanolone

Tinnitus

Phase 2 · small_molecule · completed

1 trials project

Gocovri (extended-release amantidine)

Radiation Encephalopathy

Phase 2 · small_molecule · active

1 trials project

IR Viloxazine

Attention-Deficit/Hyperactivity Disorder (ADHD)

Phase 2 · small_molecule · completed

1 trials project

IR-TPM (Topamax)

Migraine

Phase 2 · small_molecule · terminated

1 trials project

Molindone

Impulsive Aggression Comorbid With ADHD in Children

Phase 2 · small_molecule · completed

1 trials project

NV-5138

Treatment Resistant Depression

Phase 2 · small_molecule · completed

1 trials

Drugs (1)

drug

viloxazine hydrochloride

VILOXAZINE HYDROCHLORIDE

Patents (8)

patent

US 12121523

Method of treatment of attention deficit/hyperactivity disorder (ADHD)

Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11911368

Method of treatment of CNS disorders

Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11896599

Modified release preparations containing oxcarbazepine and derivatives thereof

Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11638708

Method of treatment of aggression

Expires Mon Apr 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11458143

Method of treatment of attention deficit/hyperactivity disorder (ADHD)

Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11351120

Use of higher doses of modified release huperzine formulations

Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11324753

Method of treatment of attention deficit/hyperactivity disorder (ADHD)

Expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11166960

Modified release preparations containing oxcarbazepine and derivatives thereof

Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)